The invention is directed to a pharmaceutical composition comprising: (a) naproxen sodium (b) lactic acid in an amount of from 0.2 to 1.0 mole equivalents per mole of the naproxen sodium (c) polyethylene glycol and (d) a solubilizer selected from glycerin, polyvinylpyrrolidone, propylene glycol, or combinations thereof. The compositions of the invention may be encapsulated in a softgel capsule.
